IP Library › Granted Patent US 12,403,101
Granted Patent B2
US 12,403,101 · App. 18/366,183 · Granted Sep 2, 2025

Method of treating post-traumatic stress disorder

Inventors: Dennis S. Charney (Chappaqua, NY); Adriana Feder (New York, NY)
Assignee: Icahn School of Medicine at Mount Sinai
A61K31/135A61K9/0019A61K9/0043A61K31/428A61K31/445A61K31/4525A61K31/517A61K31/53A61K33/00A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,403,101
App. No.
18/366,183
Granted
Sep 2, 2025
Kind
B2
Abstract

The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder.

Claims (17)

1. A method of treating PTSD which comprises administering to a subject diagnosed by a psychiatrist as being afflicted with PTSD, multiple doses of a pharmaceutical formulation containing a therapeutically effective amount of ketamine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, whereby the PTSD is relieved.

2. The method of claim 1 wherein the therapeutically effective amount of ketamine or a pharmaceutically acceptable salt thereof is between 0.1 mg/kg per day to about 3.0 mg/kg per day.

3. The method of claim 1 wherein the (ketamine or a pharmaceutically acceptable salt thereof is administered parenterally.

4. The method of claim 1 , wherein the ketamine or a pharmaceutically acceptable salt thereof is administered intravenously.

5. The method of claim 1 wherein the ketamine or a pharmaceutically acceptable salt thereof is administered in an amount in the range of from about 0.1 mg/kg to about 1.5 mg/kg.

6. The method of claim 1 , wherein the ketamine or a pharmaceutically acceptable salt thereof is administered in an amount in the range of from about 0.01 mg/kg to about 0.75 mg/kg.

7. The method of claim 1 , wherein the ketamine or a pharmaceutically acceptable salt thereof is administered in an amount in the range of from about 0.05 mg/kg to about 0.5 mg/kg.

8. The method of claim 1 , wherein the ketamine or a pharmaceutically acceptable salt thereof is administered in an amount of about 0.2 mg/kg or in an amount of about 0.4 mg/kg.

9. The method of claim 1 wherein the ketamine comprises esketamine.

10. The method of claim 7 wherein the ketamine or a pharmaceutically acceptable salt thereof is administered in an amount in the range of from about 0.01 mg/kg to about 1.5 mg/kg.

11. The method of claim 1 which comprises co-administering a second agent with the pharmaceutical formulation.

12. The method of claim 11 wherein the second agent is anti-depressant agent.

13. The method of claim 1 which comprises administering the pharmaceutical formulation weekly or biweekly.

14. The method of claim 1 which comprises administering an initial dose of the pharmaceutical formulation followed by titration to a lower dose of the pharmaceutical formulation.

15. A method of treating PTSD which comprises administering to a subject diagnosed by a psychiatrist as being afflicted with PTSD, a first dose of a pharmaceutical formulation containing a therapeutically effective amount of ketamine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient,

assessing the subject's response to the first dose, and

adjusting the quantity of ketamine or a pharmaceutically acceptable salt thereof present in subsequent doses administered to the subject based on the subject's response to the first dose, whereby the PTSD is relieved.

Continuity (6)
Continuation 16674381 · Nov 5, 2019
Continuation 14974576 · Dec 18, 2015
Continuation 14783686
Provisional Application 61915947 · Dec 13, 2013
Provisional Application 61811681 · Apr 12, 2013
Related Publication 20230381118A1 · Nov 30, 2023
References Cited (257)
US 4925673A · Steiner et al. · 1990 [cited by applicant]
US 5013556A · Woodle et al. · 1991 [cited by applicant]
US 5024998A · Bodor · 1991 [cited by applicant]
US 5543434A · Weg · 1996 [cited by applicant]
US 7973043B2 · Migaly · 2011 [cited by applicant]
US 8785500B2 · Charney et al. · 2014 [cited by applicant]
US 9539220B2 · Charney et al. · 2017 [cited by applicant]
US 9592207B2 · Charney et al. · 2017 [cited by applicant]
US 10765646B2 · During · 2020 [cited by applicant]
US 20040138298A1 · Mermelstein · 2004 [cited by applicant]
US 20040265364A1 · Ozturk et al. · 2004 [cited by applicant]
US 20070287753A1 · Charney · 2007 [cited by applicant]
US 20080305077A1 · Frey et al. · 2008 [cited by applicant]
US 20100298305A1 · Capehart · 2010 [cited by applicant]
US 20130165425A1 · Gless · 2013 [cited by applicant]
US 20130236573A1 · Singh · 2013 [cited by applicant]
US 20140057988A1 · Weg · 2014 [cited by applicant]
US 20140079740A1 · Salama · 2014 [cited by applicant]
US 20140256821A1 · Charney et al. · 2014 [cited by applicant]
US 20150056308A1 · Charney et al. · 2015 [cited by applicant]
US 20150057317A1 · McCarthy et al. · 2015 [cited by applicant]
US 20170151191A1 · Charney et al. · 2017 [cited by applicant]
US 20170181966A1 · Charney et al. · 2017 [cited by applicant]
US 20200253894A1 · Charney et al. · 2020 [cited by applicant]
US 20200276186A1 · Lawson et al. · 2020 [cited by applicant]
US 20240261238A1 · Fields et al. · 2024 [cited by applicant]
CN 101247795 · 2008 [cited by applicant]
CN 101466364 · 2009 [cited by applicant]
DE 102007009888 · 2008 [cited by applicant]
JP 2011504163 · 2011 [cited by applicant]
WO WO2004045601 · 2004 [cited by applicant]
WO WO2006121560 · 2006 [cited by applicant]
WO WO2007111880 · 2007 [cited by applicant]
WO WO2008118785 · 2008 [cited by applicant]
WO WO2013138322 · 2013 [cited by applicant]
WO WO2014020155 · 2014 [cited by applicant]
WO WO2020176276 · 2020 [cited by applicant]
ClinicalTrials.gov ID NCT00749203, Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD) (KetPTSD), 2008, downloaded from https://clinicaltrials.gov/study/NCT00749203?term=nct00749203&rank=1&tab=table&… [cited by examiner]
Kharasch et al., Anesthesiology Dec. 1992, vol. 77, 1201-1207 (Year: 1992). [cited by examiner]
Yanagihara et al., Drug Metabolism and Disposition Jun. 2001, 29 (6) 887-890 (Year: 2001). [cited by examiner]
Hijazi et al., Drug Metabolism and Disposition Jul. 2002, 30 (7) 853-858 (Year: 2002). [cited by examiner]
“Antidepressant Use in Children, Adolescents, and Adults”, U.S. Food and Drug Administration, Protecting and Promoting Your Health, http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/UCM096273, dated May 2, 2007… [cited by applicant]
“Leading Causes of Death”, Centers for Disease Control and Prevention, CDC 2417; Saving Lives, Protecting People, http://www.cdc.gov/nchs/fastats/leading-causes-o f-death .htm, page last updated on Sep. 30, 2015 and Dow… [cited by applicant]
Aan het Rot et al., “Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression,” Biol Psychiatry, Jan. 15, 2010, 67(2):139-45. [cited by applicant]
Aitken, “Measurement of feelings using visual analogue scales,” Proc. Royal Soc. Medicine, Oct. 1969, 62(10):989-93. [cited by applicant]
Anand et al., “Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists,” Arch. Gen. Psychiatry, Mar. 2000, 57(3):270-… [cited by applicant]
Aram et al., “Neocortical epileptogenesis in vitro: studies with N-methyl-D-aspartate, phencyclidine, sigma and dextromethorphan receptor ligands,” J Pharmacol Exp Therapy, Jan. 1989, 248(1):320-8. [cited by applicant]
Azevedo et al., “Transdermal ketamine as an adjuvant for postoperative analgesia after abdominal gynecological surgery using Lidocaine epidural blockade,” Anesth. Analgesia, Dec. 2000, 91(6):1479-82. [cited by applicant]
Bajor et al., “The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Posttraumatic Stress Disorder,” Harvard Review of Psychiatry Sep./Oct. 2011, 19(5):240-258. [cited by applicant]
Beck et al., “Assessment of depression: the depression inventory,” Modern Problems Pharmacopsychiatry, 1974, 7(0):151-69. [cited by applicant]
Berman et al., “Antidepressant effects of ketamine in depressed patients,” Biol Psychiatry, Feb. 2000, 47:351-4. [cited by applicant]
Bolshakov et al., “Determinants of trapping block of N-methyl-d-aspartate receptor channels,” J. Neurochemistry, Oct. 2003, 87(1):56-65. [cited by applicant]
Bonanno, “Ketamine in war/tropical surgery (a final tribute to the racemic mixture),” Injury, May 2002, 33(4):323-7. [cited by applicant]
Borsato et al., “Ketamine in seizure management and future pharmacogenomic considerations,” The Pharmacogenomics Journal, Nov. 27, 2019. [cited by applicant]
Bovill et al., “Alterations in response to somatic pain associated with anaesthesia,” Br. J. Anaesthesia, May 1971, 43(5):496-499. [cited by applicant]
Boyer et al., “Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain: a quantitative in situ hybridization study,” J. Mal. Neuroscience, Jun. 1998, 10(3)… [cited by applicant]
Brodie, “Road to refractory epilepsy: the Glasgow story,” Epilepsia. May 2013, 54 Suppl 2:5-8. [cited by applicant]
Byrd et al., Behavioral effects of phencyclidine and ketamine alone and in combination with other drugs, Eur. J. Pharmacol., Dec. 15, 1987, 144(3):331-341. [cited by applicant]
Calabrese et al., “A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression,” Lamictal 602 Study Group, J. Clin. Psychiatry, Feb. 1999, 60(2):79-88. [cited by applicant]
Carr et. al., “Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study,” Pain, 2004, 108(1-2):17-2… [cited by applicant]
Charney, “Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD) (KetPTSD)”, U.S. National Library of Medicine, ClinicalTrials.gov., 9 pages, last updated on Dec. 12, 2012. [cited by applicant]
Chedekel, “Yale: ‘Magic’ Antidepressant May Hold Promise For PTSD”, Jun. 3, 2012, The Hartford Courant, http:/!4 ˜rticles. courant.com/2012-06-03/health/hc-yale-drug-research-20120601_1 _ptsd-debil itating-anxiety-disor… [cited by applicant]
Chong et al., “Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: Preliminary findings from a three-way randomized, crossover study,” Clin Drug Investigation, May 2009, 29(5):317-24. [cited by applicant]
Clinicaltrials.gov, [online] “Rapid Antidepressant Effects of Ketamine in Major Depression,” Aug. 2, 2004, retrieved on May 7, 2020, retrieved from URL https://clinicaltrials.gov/ct2/show/study/NCT00088699?id=00088699&d… [cited by applicant]
Correll et al., “Two case studies of patients with major depressive disorder given low- dose (subanesthetic) ketamine infusions,” Pain Med., Jan.-Feb. 2006, 7(1):92-5. [cited by applicant]
De Vry et al., “Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine,” Behav. Pharmacology, May 2003, 14(3):229-35. [cited by applicant]
Debattista et al., “Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind. placebo-controlled study,” Am. J. Psychiatry, Aug. 2000, 157(8):1334-7. [cited by applicant]
Dingledine et al., “The glutamate receptor ion channels,” Pharmacol Rev. Mar. 1999, 51(1):7-61. [cited by applicant]
Domino et al., “Pharmacologic effects of ci-581, a new dissociative anesthetic in man,” Clin. Pharmacol. Therapeutics, May 1965, 6(3):279-291. [cited by applicant]
Drevets et al., “Amphetamine-induced effects of ci-581, a new diissociative anesthetic in man,” Clin. Pharmacol. Therapeutics, May 1965, 6(3):279-291. [cited by applicant]
D'sa et al., “Antidepressants and neuroplasticity,” Bipolar Disorders, Jun. 14, 2002, 4(3):183-94. [cited by applicant]
Duman, “Synaptic plasticity and mood disorders,” Mol. Psychiatry, Mar. 18, 2002, 7:829-834. [cited by applicant]
Elliot et al., “N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development,” Neuropsychopharmacology, Dec. 1, 1995, 13(4):347-356. [cited by applicant]
Entsuah et al., “Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo,” J. Clin. Psychiatry, Nov. 2001, 62… [cited by applicant]
Esaian et al., “Ketamine continuous infusion for refractory status epilepticus in a patient with anticonvulsant hypersensitivity syndrome,” Ann Pharmacotherapy, Nov. 2013, 47: 1569-76. [cited by applicant]
Esbensen et al., “Reliability and validity of an assessment instrument for anxiety, depression, and mood among individuals with mental retardation,” J Autism Dev. Disorders, Dec. 2003, 33(6), 617-629. [cited by applicant]
Extended European Search Report in European Appln. No. 14783146.5, mailed on Dec. 19, 2016, 7 pages. [cited by applicant]
Fava, “Diagnosis and definition of treatment-resistant depression,” Biol. Psychiatry, Apr. 15, 2003, 53(8):649-659. [cited by applicant]
Feder et al., “Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial,” JAMA Psychiatry. Jun. 2014, 71(6):681-8. [cited by applicant]
Frank et al., “Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence,” Arch. Gen. Psychiatry, Sep. 1991, 48(9):851-855. [cited by applicant]
Freeman et al., “Phencyclidine raises kindled seizure thresholds,” Pharmacol Biochem Behavior, Jun. 1982, 16(6):1009-11. [cited by applicant]
Friedberg, “Hypnosis First, The Dissociation,” Anesth. Analgesia, Mar. 2003, 96(3):914. [cited by applicant]
Fujikawa, “Neuroprotective effect of ketamine administered after status epilepticus onset,” Epilepsia, Feb. 1995, 36(2): 186-95. [cited by applicant]
Gaspard et al., “Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study,” Epilepsia, Aug. 2013, 54(8):1498-503. [cited by applicant]
Gill et al., “Depression screening tools in persons with epilepsy: A systematic review of validated tools,” Epilepsia, May 2017, 58(5):695-705. [cited by applicant]
Gongfu et al., “New Uses and Combinations of Clinical Drugs,” People's Medical Publishing House, Aug. 1999, p. 130 (English abstract). [cited by applicant]
Greist, “Posttraumatic Stress Disorder (PTSD),” Merck Manuals, May 2014, retrieved on Mar. 25, 2016, available online <https://www.merckmanuals.com/professional/psychiatric-disorders/anxiety-and- stressor-related-disord… [cited by applicant]
Gutzke et al., “Cardiac transplantation: a prospective comparison of ketamine and sufentanil for anesthetic induction,” J. Cardiothorac. Anesthesia, Aug. 1989, 3(4):389-95. [cited by applicant]
Hamilton, “A rating scale for depression,” J. Neural. Neurosurg. Psychiatry, Feb. 1960, 23(1):56-62. [cited by applicant]
Hara et al., “Recent findings on drug therapy of PTSD,” Traumatic Stress, 2006, 4(1):65-67. [cited by applicant]
Hedlund et al., “The Hamilton rating scale for depression,” J. Operational Psychiatry, 1979, 10(2):149-65. [cited by applicant]
Hesdorffer et al., “Epilepsy, suicidality, and psychiatric disorders: a bidirectional association,” Ann Neurology, Aug. 2012, 72(2):184-91. [cited by applicant]
Holmes, et al., “Cross talk between drug-resistant epilepsy and the gut microbiome,” Epilepsia, Dec. 2020, 61(12):2619-2628. [cited by applicant]
Hsieh et al., “Terminating prolonged refractory status epilepticus using ketamine,” Clin Neuropharmacology, May 2010, 33:165-7. [cited by applicant]
Husain et al., “Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report”, J. Clin. Psychiatry, Apr. 2004, 65(4):485-91. [cited by applicant]
Hustveit et al., “Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors,” Pharmacol. Toxicology, Dec. 1995, 77(6):355-9. [cited by applicant]
Hyman et al., “Initiation and adaptation: a paradigm for understanding psychotropic drug action,” Am. J. Psychiatry, Feb. 1996, 153(2):151-62. [cited by applicant]
International Preliminary Report on Patentability in International Appln No. PCT/CN2019/095364, mailed on Jan. 28, 2021, 6 pages. [cited by applicant]
International Preliminary Report on Patentability in International Appln No. PCT/US2022/031245, mailed on Dec. 7, 2023, 7 pages. [cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2007/006898, mailed on Sep. 23, 2008, 4 pages. [cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2014/033997, mailed on Oct. 22, 2015, 10 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/CN2019/095364, mailed on Sep. 29, 2019, 6 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2007/06898 mailed on Nov. 9, 2007, 3 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2014/033997 mailed on Aug. 27, 2014, 12 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2022/031245, mailed on Aug. 19, 2022, 9 pages. [cited by applicant]
Jick et al., “Antidepressants and the risk of suicidal behaviors,” JAMA, Jul. 21, 2004, 292(3):338-43. [cited by applicant]
Kalilani et al., “The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis,” Epilepsia, Dec. 2018, 59(12):2179-2193. [cited by applicant]
Kane et al., “Clozapine and haloperidol in moderately refractory schizophrenia: a 6- month randomized and double- blind comparison,” Arch. Gen. Psychiatry, Oct. 2001, 58(10):965-72. [cited by applicant]
Kapur et al., “Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine 02 receptor,” Biol. Psychiatry, Jun. 1, 2001, 49(11):954-7. [cited by applicant]
Kapur et al., “NMDA receptor activation mediates the loss of GABAergic inhibition induced by recurrent seizures,” Epilepsy Research, Mar. 1990, 5(2):103-11. [cited by applicant]
Keller, “Issues in treatment-resistant depression,” J. Clin. Psychiatry, 2005, 66(8):5-12. [cited by applicant]
Kessler et al., “Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication,” Arch. Gen. Psychiatry, Jun. 2005, 62(6):593-602. [cited by applicant]
Kramer et al., “Severe refractory status epilepticus owing to presumed encephalitis,” J Child Neurology, Mar. 2005, 20(3):184-7. [cited by applicant]
Kramer, “Early ketamine to treat refractory status epilepticus,” Neurocrit Care, Apr. 2012,16(2):299-305. [cited by applicant]
Krystal et al., “Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function,” Arch. Gen. Psychiatry,… [cited by applicant]
Krystal et al., “Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments,” Mol. Psychiatry, 2002, 7:S71-S80. [cited by applicant]
Krystal et al., “Interactive effects of subanesthetic ketamine and haloperidol in healthy humans,” Psychopharmacology (Berl.), Jul. 1999, 145(2):193-204. [cited by applicant]
Krystal et al., “Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans,” Psychopharmacology (Berl.), Jan. 1998, 135(3):213-229. [cited by applicant]
Krystal et al., “Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor ago… [cited by applicant]
Krystal et al., “Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses,” Arch. Gen. Psychiatry, Mar. 1994, 51(3):199-214. [cited by applicant]
Kudoh et al., “Small-dose ketamine improves the postoperative state of depressed patients,” Anesth. & Analgesia, Jul. 2002, 95(1):114-8. [cited by applicant]
Kwan et al., “Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies,” Epilepsia, Jun. 2010, 51:1069- 77 [Erratum, Epilepsia 2010;51:1922.] [cited by applicant]
Lang et al., “Molecular and cellular dissection of NMDA receptor subtypes as antidepressant targets,” Neurosci Biobehav Reviews, Jan. 2018, 84:352-358. [cited by applicant]
Lapidus et al., “A randomized controlled trial of intranasal ketamine in major depressive disorder,” Biol Psychiatry, Dec. 15, 2014, 76(12):970-6. [cited by applicant]
Lawn et al., “Injuries due to seizures in persons with epilepsy: a populationbased study,” Neurology, Nov. 9, 2004, 63(9):1565-70. [cited by applicant]
Layer et al., “Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715),” Pharmacol. Biochem. Behavior, Nov. 1, 1995, 52(3):621-7. [cited by applicant]
Lee et al., “NMDA receptors offer more than one functionality,” Anesth. Analgesia, May 1, 2003, 96(5):1533-4. [cited by applicant]
Lent et al., “Ketamine and Treatment-Resistant Depression,” AANA Journal, Oct. 2019, 87(5):411-419. [cited by applicant]
Lindefors et al., “Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex,” Brain Research, Jun. 13, 1997, 759(2):205-12. [cited by applicant]
Louon et al., “Sedation with nasal ketamine and midazolam for cryotherapy in retinopathy of prematurity,” Br. J. Ophthalmology, Aug. 1993, 77(8):529-30. [cited by applicant]
Maler et al., “Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons,” Brain Research, Aug. 9, 2005, 1052(2):156-62. [cited by applicant]
Manji et al., “Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression,” Biol. Psychiatry, Apr. 15, 2003, 53(8):707-42. [cited by applicant]
Marangell et al., “Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients,” Arch. Gen. Psychiatry, Mar. 1, 1997, 54(3):214-22. [cited by applicant]
Marchand et al. “Evidence for a monoamine medicated, opioid-independent, antihyperalgesic effect of venlafaxine, a nontricyclic antidepressant, in a neurogenic pain model in rats,” Pain, Jun. 1, 2003, 103(3):229-235. [cited by applicant]
Marlow et al., “Haemodynamic response to induction of anaesthesia with ketamine/midazolam,” Can. J. Anaesthesia, Oct. 1991, 38(7):844-8. [cited by applicant]
Mathew et al., “Glutamate modulators as novel interventions for mood disorders,” Brazilian Journal of Psychiatry, Sep. 2005, 27(3):243-8. [cited by applicant]
Mathew et al., “Ketamine for Treatment-Resistant Unipolar Depression”, CNS Drugs, Mar. 2012, 26: 189-204. [cited by applicant]
Mazarati et al., “N-methyl-D-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat,” Neurosci Letters, Apr. 23, 1999, 265(3):187-90. [cited by applicant]
McCagh et al., “Epilepsy, psychosocial and cognitive functioning,” Epilepsy Research, Sep. 2009, 86: 1-14. [cited by applicant]
McGhee et al., “The Correlation Between Ketamine and Posttraumatic Stress Disorder in Burned Service Members,” Journal of TRAUMA Injury, Infection, and Critical Care, Feb. 2008, 64(2):s195-s199. [cited by applicant]
Mclean et al., “Ketamine concentrations during cardiopulmonary bypass,” Can. J. Anaesthesia, Jun. 1996, 43(6):580-4. [cited by applicant]
Meloni et al., “Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats,” Pharmacol. Biochem. Behavior, Oct. 1, 2003, 46(2):423-6. [cited by applicant]
Mewasingh et al., “Oral ketamine in paediatric non-convulsive status epilepticus,” Seizure, Oct. 2003, 12(7):483-9. [cited by applicant]
Ming Wen, “Olfactory targeting through intranasal delivery of biopharmaceutical drugs to the brain: current development,” Discov. Med., Jun. 13, 2011, 11(61):497-5033. [cited by applicant]
Mohanraj et al., “Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study,” Lancet Neurology, May 3, 2006, 5(6):481-7. [cited by applicant]
Moryl et al., “Potential antidepressive properties of amantadine, memantine and bifemelane,” Pharmacol. Toxicology, Jun. 1993, 72(6):394-7. [cited by applicant]
Murray et al., “Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study,” Lancet, May 17, 1997, 349(9063):1436-42. [cited by applicant]
Murrough et al., “Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial,” Am J Psychiatry, Oct. 1, 2013, 170(10):1134-42. [cited by applicant]
Murrough et al., “Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial,” Mar. 13, 2015, 40(5):1084-90. [cited by applicant]
Murrough et al., “Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression,” Biol Psychiatry, Jul. 30, 2012, 74(4):250-6. [cited by applicant]
Narita et al., “Role of the NMDA receptor subunit in the expression of the discriminative stimulus effect induced by ketamine,” Eur. J. Pharmacology, Jun. 29, 2001, 423:41-46. [cited by applicant]
Newcomer et al., “Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis,” Neuropsychopharmacology, Feb. 1999, 20(2):106-18. [cited by applicant]
Niciu et al., “Clinical predictors of ketamine response in treatment-resistant major depression,” J Clin Psychiatry, May 2014, 75(5):e417-23. [cited by applicant]
Niciu et al., “Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder,” J Neural Transmission (Vienna), Aug. 2014, 121(8):907-24. [cited by applicant]
Nierenberg et al., “A Comparison of Lithium and T3 Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report,” Am J Psychiatry, Sep. 2006, 163(9):1519-30. [cited by applicant]
Noppers et al., “Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: A randomized, prospective, double blind, active placebo-controlled trial,” Eur. J. of Pain, Oct. 2011. [cited by applicant]
Office Action for U.S. Appl. No. 14/783,686, mailed on Dec. 12, 2016, 15 pages. [cited by applicant]
Office Action in Australian Appln. No. 2014250756, mailed on Jun. 7, 2018, 4 pages. [cited by applicant]
Office Action in Canadian Appln. No. 2909357, mailed on Oct. 28, 2020, 7 pages. [cited by applicant]
Office Action in Chinese Appln. No. 201480033664.6, mailed on Aug. 7, 2017, 20 pages (with English translation). [cited by applicant]
Office Action in Chinese Appln. No. 201480033664.6, mailed on Mar. 22, 2018, 19 pages (with English Translation). [cited by applicant]
Office Action in Chinese Appln. No. 201480033664.6, mailed on Nov. 1, 2018, 17 pages (with English Translation). [cited by applicant]
Office Action in Chinese Appln. No. 201480033664.6, mailed on Oct. 18, 2019, 14 pages (with English translation). [cited by applicant]
Office Action in Chinese Appln. No. 202010884736.5, mailed on Jan. 11, 2022, 25 pages (with English Translation). [cited by applicant]
Office Action in Chinese Appln. No. 202010884736.5, mailed on Jun. 16, 2021, 23 pages (with English Translation). [cited by applicant]
Office Action in Chinese Appln. No. 202010884736.5, mailed on May 5, 2022, 23 pages (with English Translation). [cited by applicant]
Office Action in European Appl. No. 22812212.3, mailed on Jan. 19, 2024, 3 pages. [cited by applicant]
Office Action in Israeli Application No. 242007, dated Jun. 7, 2018, 7 pages. [cited by applicant]
Office Action in Israeli Appln. No. 242007, mailed on Jun. 16, 2019, 6 pages (with Machine Translation) . [cited by applicant]
Office Action in Japanese Appln. No. 2016-507700, mailed on Jan. 30, 2018, 5 pages (English translation). [cited by applicant]
Office Action in Korean Appln. No. 10-2015-7032043, mailed on Aug. 28, 2020, 16 pages (with English Translation). [cited by applicant]
Office Action in Korean Appln. No. 10-2015-7032043, mailed on Mar. 29, 2021, 7 pages (with English Translation). [cited by applicant]
Office Action in Korean Appln. No. 10-2021-7013044, mailed on Aug. 18, 2021, 19 pages (with English Translation). [cited by applicant]
Office Action in Korean Appln. No. 10-2021-7013044, mailed on Feb. 23, 2022, 7 pages (with English Translation). [cited by applicant]
Office Action in Korean Appln. No. 10-2022-7010053, mailed on May 24, 2022, 4 pages (with English Translation). [cited by applicant]
Office Action in Mexican Appln. No. MX/a/2015/014385, mailed on Aug. 29, 2019, 7 pages (with English Translation). [cited by applicant]
Office Action in Mexican Appln. No. MX/a/2015/014385, mailed on Feb. 25, 2019, 10 pages (with English Translation). [cited by applicant]
Office Action in Mexican Appln. No. MX/a/2015/014385, mailed on Sep. 27, 2018, 7 pages (with English Translation). [cited by applicant]
Office Action in New Zealand Appln. No. 713300, mailed on Nov. 25, 2019, 3 pages. [cited by applicant]
Oshima et al., “Continuous subcutaneous injection of ketamine for cancer pain,” Can. J. Anaesthesia, Apr. 1990, 37(3):385-6. [cited by applicant]
Ostroff et al., “Antidepressant effect of ketamine during ECT,” Am. J. Psychiatry, Jul. 1, 2005, 162(7):1385-6. [cited by applicant]
Overall et al., “The brief psychiatric rating scale,” Psychol. Reports, 1962, 10:799-812. [cited by applicant]
Papp et al., “Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression,” Eur. J. Pharmacology, Sep. 22, 1994, 263(1-2): 1-7. [cited by applicant]
Paskalis et al., “Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series,” Pharmacopsychiatry, Jan. 2010, 43(1):33-5. [cited by applicant]
Paul et al., “Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases,” World J. of Bio. Psychiatry, Aug. 13, 2009, 10(3):241-4. [cited by applicant]
Price et al., “Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression,” Biol Psychiatry, Sep. 1, 2009, 66(5):522-526. [cited by applicant]
Prüss et al., “Ketamine successfully terminates malignant status epilepticus,” Epilepsy Research, Dec. 2008, 82(2-3):219-222. [cited by applicant]
Przegaliński et al., “Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist,” Neuropharmacology, Jan. 1997, 36(1):31-7. [cited by applicant]
Quevedo et al., “Ketamine induces rapid onset of antidepressant action: neurophysiological biomarkers as predictors of effect,” Biomarkers Medicine, 2009, 3(1):5-8. [cited by applicant]
Rosati et al., “Ketamine for Refractory Status Epilepticus: A Systematic Review,” Sep. 19, 2018, 32(11):997-1009. [cited by applicant]
Rothman, “Noncompetitive N-methyl-D-aspartate antagonists affect multiple ionic currents,” J. Pharmacol. Exp. Therapeutics, Jul. 1, 1988, 246(1):137-42. [cited by applicant]
Rowland, “Subanesthetic Ketamine: How It Alters Physiology and Behavior in Humans,” Aviat Space Environ Medicine, Jul. 1, 2005, 76(7 Suppl):C52-8, 7 pages. [cited by applicant]
Rumfield et al., “A brief report of research: Evaluating the effects of ketamine on memory in posttraumatic stress disorder,” Dimensions of Critical Care Nursing, Mar./Apr. 2009, 28(2):83. [cited by applicant]
Rush et al., “Research issues in the study of difficult-to-treat depression,” Biol. Psychiatry, Apr. 15, 2003, 53(8):743-53. [cited by applicant]
Sackeim et al., “Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome,” Neuropsychopharmacology, Nov. 2001, 25(5):713-728. [cited by applicant]
Sackeim, “The definition and meaning of treatment-resistant depression,” J. Clin. Psychiatry, Jan. 2001, 62(S16):10-17. [cited by applicant]
Sadove et al., Analgesic effects of ketamine administered in subdissociative doses, Anesth. Analgesia, May-Jun. 1971, 50(3):452-7. [cited by applicant]
Sanacora et al., “Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression,” Arch. Gen. Psychiatry, Jul. 2004, 61(7):705-13. [cited by applicant]
Sapolsky, “Is impaired neurogenesis relevant to the affective symptoms of depression?,” Biol. Psychiatry, Aug. 1, 2004, 56:137-139. [cited by applicant]
Schmidt et al., “Cerebral physiological responses to bolus injection of racemic, S(+)- or R(−) -ketamine in the pig,” ACTA Anaesthesiologica Scandinavica, 2005, 49:1436-1442. [cited by applicant]
Schonenberg et al., “Effects of peritraumatic ketamine medication on early and sustained posttraumatic stress symptoms in moderately injured accident victims,” Psychopharmacology, 2005, 182(3):420-5. [cited by applicant]
Schonenberg et al., “Ketamine aggravates symptoms of acute stress disorder in a naturalistic sample of accident victims,” J Psychopharmacol, Jul. 2008, 22: 493-7. [cited by applicant]
Schulenberg et al., “Logotherapy for clinical practice,” Psychotherapy (Chic), Dec. 2008, 45(4):447-63. [cited by applicant]
Scott et al., “Anxiety and depressive disorders in people with epilepsy: A meta- analysis,” Epilepsia, Jun. 2017, 58(6):973-982. [cited by applicant]
Sheth et al., “Refractory status epilepticus: response to ketamine,” Neurology, Dec. 1998, 51(6): 1765-6. [cited by applicant]
Skolnick et al., “Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression,” Pharmacopsychiatry, Jan. 1996, 29(1):23-6. [cited by applicant]
Skolnick, “Antidepressants for the new millennium,” Eur. J. Pharmacology, Jun. 30, 1999, 375(1-3):31-40. [cited by applicant]
Skolnick, “Modulation of glutamate receptors: strategies for the development of novel antidepressants,” Amino Acids, Sep. 2002, 23(1):153-9. [cited by applicant]
Smith et al., “Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolismof monoamines,” Neuropharmacology, Apr. 1981, 20(4):391-6. [cited by applicant]
Sofia et al., “Evaluation of ketamine HCI for anti-depressant activity,” Arch. Int. de Pharacodynamie et de Therapie, Mar. 1, 1975, 214(1):68-74. [cited by applicant]
Spitzer et al., “A brief measure for assessing generalized anxiety disorder: the GAD-7,” Arch Intern Medicine, May 22, 2006, 166(10):1092-7. [cited by applicant]
Stannard et al., “Ketamine hydrochloride in the treatment of phantom limb pain,” Pain, Aug. 1993, 54(2):227-30. [cited by applicant]
Supplementary European Search Report in European Appln. No. 07753520.1, mailed on Feb. 10, 2010, 7 pages. [cited by applicant]
Synowiec et al., “Ketamine use in the treatment of refractory status epilepticus,” Epilepsy Research, Jul. 2013, 105(1-2):183-8. [cited by applicant]
Tarocco et al., “Use of ketamine in a newborn with refractory status epilepticus: a case report,” Pediatr Neurology, Jul. 2014, 51(1):154-6. [cited by applicant]
Thase et al., “Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials,” J. Clin. Psychiatry, Aug.… [cited by applicant]
Thase et al., “When at first you don't succeed: sequential strategies for antidepressant nonresponders,” J. Clin. Psychiatry, Jan. 1997, 58(13):23-9. [cited by applicant]
Trivedi et al., “Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice,” Am. J. Psychiatry, Jan. 2006, 163(1):28-40. [cited by applicant]
Trullas et al., “Functional antagonists at the NMDA receptor complex exhibit antidepressant actions,” Eur. J. Pharmacology, Aug. 21, 1990, 185(1):1-10. [cited by applicant]
Ubogu et al., “Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity,” Epilepsy & Behavior, Feb. 2003, 4(1):70-5. [cited by applicant]
Vranken et al., “Iontophoretic administration of S(+}-ketamine in patients with intractable central pain: a placebo-controlled trial,” Pain. Nov. 2005, 118(1- 2):224-31. [cited by applicant]
Walker et al., “Diagnosis and treatment of status epilepticus on a neurological intensive care unit,” QJM, Dec. 1, 1996, 89(12):913-20. [cited by applicant]
Wang et al., “NMDA/NR2B selective antagonists in the treatment of ischemic brain injury,” Curr. Drug Targets CNS Neural. Disord, Apr. 2005, 4(2):143-51. [cited by applicant]
Wanna et al., “A comparison of propofol and ketamine as induction agents for cesarean section,” J. Med. Assoc. Thailand, Jul. 2004, 87(7):774-9. [cited by applicant]
Weksler et al., “Nasal ketamine for paediatric premedication,” Can. J. Anaesthesia, Feb. 1993, 40(2):119-21. [cited by applicant]
White et al., “Comparative pharmacology of the ketamine isomers,” Br. J. Anaesthesia, Feb. 1985, 57(2):197-203. [cited by applicant]
Wirz-Justice et al., “Sleep deprivation in depression: what do we know, where do we go?,” A237 Biol. Psychiatry, Aug. 15, 1999, 46(4):445-53. [cited by applicant]
Womble, “Effects of Ketamine on Major Depressive Disorder in a Patient with Posttraumatic Stress Disorder,” AANA Journal, Apr. 1, 2013, 81(2):118-119. [cited by applicant]
Yeh et al., “Oral ketamine controlled refractory nonconvulsive status epilepticus in an elderly patient,” Seizure, 2011, 20(9):723-6. [cited by applicant]
Yilmaz et al., “Prolonged effect of an anesthetic dose of ketamine on behavioral despair,” Pharmacol. Biochem. Behavior, Jan.-Feb. 2002, 71(1-2):349-352. [cited by applicant]
Young et al., “A rating scale for mania: reliability, validity and sensitivity,” Br. J. Psychiatry, 1978, 133:429-435. [cited by applicant]
Zarate et al., “A randomized trial of an N-methyl-D-aspartate antagonist in treatment- resistant major depression,” Arch Gen Psychiatry, Aug. 2006, 63(8):856-64. [cited by applicant]
Zarate et al., “An open-label trial of riluzole in patients with treatment-resistant major depression,” Am J Psychiatry, Jan. 2004, 161(1):171-4. [cited by applicant]
Zarate et al., “An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression,” Biol. Psychiatry. Feb. 15, 2005, 57(4):430-2. [cited by applicant]
Zarate et al., “Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders,” Psychopharmacol. Bulletin, 2002, 36(4):35-83. [cited by applicant]
Zarate et al., “Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system,” Ann. N Y Acad. Science, Nov. 2003, 1003(1):273-91. [cited by applicant]
Zarate et al., “A double-blind, placebo-controlled study of memantine in the treatment of major depression,” Am J Psychiatry, 163(1):153-155, Jan. 2006. [cited by applicant]
Zeiler et al., “Ketamine for medically refractory status epilepticus after elective aneurysm clipping,” Neurocrit Care, Aug. 2013, 19(1):119-24. [cited by applicant]
Zeiler et al., “NMDA antagonists for refractory seizures,” Neurocrit Care, Jun. 2014, 20(3):502-13. [cited by applicant]
U.S. Appl. No. 14/783,686, filed Oct. 9, 2015, Charney et al. [cited by applicant]
U.S. Appl. No. 14/974,576, filed Dec. 18, 2015, Charney et al. [cited by applicant]
U.S. Appl. No. 14/674,38, filed Nov. 5, 2019, Charney et al. [cited by applicant]
U.S. Appl. No. 18/366,183, filed Aug. 7, 2023, Charney et al. [cited by applicant]
U.S. Appl. No. 11/688,603, filed Mar. 20, 2017, Charney et al. [cited by applicant]
U.S. Appl. No. 14/306,382, filed Jun. 17, 2024, Charney et al. [cited by applicant]
U.S. Appl. No. 15/379,013, filed Dec. 14, 2016, Charney et al. [cited by applicant]
U.S. Appl. No. 15/417,689, filed Jan. 27, 2017, Charney et al. [cited by applicant]
U.S. Appl. No. 16/844,090, filed Oct. 9, 2020, Charney et al. [cited by applicant]
U.S. Appl. No. 15/930,140, filed May 12, 2020, Charney et al. [cited by applicant]
U.S. Appl. No. 18/564,527, filed Nov. 27, 2023, Fields et al. [cited by applicant]
Extended European Search Report in European Appln. No. 22812212.3, mailed on Dec. 2, 2024, 9 pages. [cited by applicant]
Fang et al., “Ketamiane for the treatment of refractory status epilepticus,” Seizure, Aug. 2015, available online May 19, 2015, 30:14-20. [cited by applicant]
Niciu et al., “A history of early life parental loss or separation is associated with successful cognitive-behavioral therapy in major depressive disorder.” Journal of Affective Disorders, Aug. 2015, 187:241-244. [cited by applicant]
Remington's Pharmaceutical Sciences, 18th ed., 1990, Chapter 89, pp. 1633-1665. [cited by applicant]
Sanders et al., “Intranasal esketamine: From originis to future implications in treatment-resistant depression,” J Psychiatr Res, May 2021, available online Feb. 19, 2021, 137:29-35. [cited by applicant]
Wearley, “Recent progress in protein and peptide delivery by noninvasive routes,” Crit. Rev. Ther. Drug Carrier Systems, 1991, 8(4):331-394. [cited by applicant]
Zarate et al., “Robust, rapid and relatively sustained antidepressant effects with a singledose of an NMDA antagonist in treatment-resistant major depression: A double-blind placebocontrolled study,” Neurosychopharmacol… [cited by applicant]